Yield10 Bioscience Stock Performance
| YTEN Stock | USD 0.01 0.00 0.00% |
Yield10 Bioscience holds a performance score of 10 on a scale of zero to a hundred. The firm maintains a market beta of 9.69, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Yield10 Bioscience will likely underperform. Use Yield10 Bioscience sortino ratio, as well as the relationship between the downside variance and rate of daily change , to analyze future returns on Yield10 Bioscience.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Yield10 Bioscience are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of very weak technical and fundamental indicators, Yield10 Bioscience displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 2.6 M | |
| Free Cash Flow | -10.1 M |
Yield10 |
Yield10 Bioscience Relative Risk vs. Return Landscape
If you would invest 33.00 in Yield10 Bioscience on December 22, 2024 and sell it today you would lose (31.50) from holding Yield10 Bioscience or give up 95.45% of portfolio value over 90 days. Yield10 Bioscience is currently generating 13.7224% in daily expected returns and assumes 104.758% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Yield10, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Yield10 Bioscience Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Yield10 Bioscience's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Yield10 Bioscience, and traders can use it to determine the average amount a Yield10 Bioscience's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.131
| Best Portfolio | Best Equity | YTEN | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 104.76 actual daily | 96 96% of assets are less volatile |
Expected Return
| 4.96 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average Yield10 Bioscience is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Yield10 Bioscience by adding it to a well-diversified portfolio.
Yield10 Bioscience Fundamentals Growth
Yield10 Stock prices reflect investors' perceptions of the future prospects and financial health of Yield10 Bioscience, and Yield10 Bioscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Yield10 Stock performance.
| Return On Equity | -15.08 | ||||
| Return On Asset | -1.78 | ||||
| Operating Margin | (7.12) % | ||||
| Current Valuation | 2.07 M | ||||
| Shares Outstanding | 692.68 K | ||||
| Price To Earning | (3.19) X | ||||
| Price To Book | 11.23 X | ||||
| Price To Sales | 0.46 X | ||||
| Revenue | 60 K | ||||
| EBITDA | (14.13 M) | ||||
| Cash And Equivalents | 10.16 M | ||||
| Cash Per Share | 2.07 X | ||||
| Total Debt | 3.21 M | ||||
| Debt To Equity | 0.28 % | ||||
| Book Value Per Share | (9.71) X | ||||
| Cash Flow From Operations | (10.07 M) | ||||
| Earnings Per Share | (20.14) X | ||||
| Total Asset | 3.91 M | ||||
| Retained Earnings | (414.15 M) | ||||
| Current Asset | 15.34 M | ||||
| Current Liabilities | 3.91 M | ||||
About Yield10 Bioscience Performance
By examining Yield10 Bioscience's fundamental ratios, stakeholders can obtain critical insights into Yield10 Bioscience's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Yield10 Bioscience is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing technologies to enable step-change increases in crop yield in the United States and Canada. Yield10 Bioscience, Inc. was incorporate in 1992 and is headquartered in Woburn, Massachusetts. Yield10 Bioscience operates under Agricultural Inputs classification in the United States and is traded on NASDAQ Exchange. It employs 29 people.Things to note about Yield10 Bioscience performance evaluation
Checking the ongoing alerts about Yield10 Bioscience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Yield10 Bioscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Yield10 Bioscience is not yet fully synchronised with the market data | |
| Yield10 Bioscience is way too risky over 90 days horizon | |
| Yield10 Bioscience has some characteristics of a very speculative penny stock | |
| Yield10 Bioscience appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 60 K. Net Loss for the year was (14.46 M) with loss before overhead, payroll, taxes, and interest of (6.46 M). | |
| Yield10 Bioscience currently holds about 10.16 M in cash with (10.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.07, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 18.0% of the company outstanding shares are owned by insiders |
- Analyzing Yield10 Bioscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Yield10 Bioscience's stock is overvalued or undervalued compared to its peers.
- Examining Yield10 Bioscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Yield10 Bioscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Yield10 Bioscience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Yield10 Bioscience's stock. These opinions can provide insight into Yield10 Bioscience's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Yield10 Bioscience. If investors know Yield10 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Yield10 Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Yield10 Bioscience is measured differently than its book value, which is the value of Yield10 that is recorded on the company's balance sheet. Investors also form their own opinion of Yield10 Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Yield10 Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Yield10 Bioscience's market value can be influenced by many factors that don't directly affect Yield10 Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Yield10 Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Yield10 Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Yield10 Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.